Ovid Therapeutics Inc. OVID
2.80 USD -0.05 (-1.75%)
At closeNov 10, 2026, 4:00 PM EST
2.80 0.00 0.00%
After hours · Nov 10, 4:00 PM ET
2.64 Day range 2.87
1.18 52-week range 3.11
- YTD
- +71.78%
- 1 year
- +107.41%
News
benzinga.com Ovid Therapeutics Q3 EPS $(0.10) Misses $(0.09) Estimate Ovid Therapeutics (NASDAQ:OVID) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate of $(0.09) by 11.11 percent. This is a 41.18 percent increase over losses of…
globenewswire.com Ovid Therapeutics Reports Business Updates and Third Quarter 2026 Financial Results OV329 is advancing in a global, Phase 2 focal epilepsy study expected to read out in H2 2027 Ovid is enrolling patients in ongoing photosensitivity study intended to demonstrate the anticonvulsant…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Karyopharm Therapeutics (NASDAQ:KPTI) stock moved upwards by 10.0% to $0.04 during Monday's after-market session. The company's market cap stands at $1.2 million. Fractyl Health (NASDAQ:GUTS)…
defenseworld.net Critical Comparison: Ovid Therapeutics (NASDAQ:OVID) & Ono Pharmaceutical (OTCMKTS:OPHLF) Ono Pharmaceutical (OTCMKTS:OPHLF - Get Free Report) and Ovid Therapeutics (NASDAQ: OVID - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the…
globenewswire.com Ovid Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
benzinga.com Wolfe Research Initiates Coverage On Ovid Therapeutics with Outperform Rating, Announces Price Target of $5 Wolfe Research initiates coverage on Ovid Therapeutics (NASDAQ:OVID) with a Outperform rating and announces Price Target of $5.
prnewswire.com Actinium Pharmaceuticals Strengthens Leadership Team with Appointment of Matt David, M.D. as Chief Financial Officer NEW YORK, Oct. 15, 2026 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE American: ATNM) ("Actinium" or the "Company"), a pioneer in the development of targeted radiotherapies, today announced…
globenewswire.com Ovid Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
defenseworld.net BlackRock Inc. Takes Position in Ovid Therapeutics $OVID BlackRock Inc. bought a new position in shares of Ovid Therapeutics (NASDAQ: OVID) during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange…
zacks.com What Makes Ovid Therapeutics (OVID) a Strong Momentum Stock: Buy Now? Does Ovid Therapeutics (OVID) have what it takes to be a top stock pick for momentum investors? Let's find out.
zacks.com Ovid Therapeutics (OVID) Reports Q2 Loss, Beats Revenue Estimates Ovid Therapeutics (OVID) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.06 per share a year ago.
globenewswire.com Ovid Therapeutics Reports Business Updates and Second Quarter 2026 Financial Results NEW YORK, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
zacks.com Earnings Preview: Ovid Therapeutics (OVID) Q2 Earnings Expected to Decline Ovid Therapeutics (OVID) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
defenseworld.net Ally Bridge Group NY LLC Has $6.26 Million Position in Ovid Therapeutics $OVID Ally Bridge Group NY LLC raised its stake in Ovid Therapeutics (NASDAQ: OVID) by 57.9% during the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange…
defenseworld.net ADAR1 Capital Management LLC Acquires 259,113 Shares of Ovid Therapeutics $OVID ADAR1 Capital Management LLC grew its holdings in Ovid Therapeutics (NASDAQ: OVID) by 6.0% in the undefined quarter, according to its most recent disclosure with the Securities and Exchange…
globenewswire.com Ovid Therapeutics Strengthens Executive Leadership Team to Support Continued Pipeline Progress and Next Phase of Development NEW YORK, July 08, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
seekingalpha.com Ovid Therapeutics: Risk-Adjusted Valuation Shows Deep Discount Despite 700% Rally Ovid Therapeutics is rated a Buy, driven by risk-adjusted undervaluation and a $193 million cash runway through 2029. OVID's lead asset, OV329, targets drug-resistant epilepsies with a differentiated…
seekingalpha.com Ovid Therapeutics: Buy Next-Gen GABA-Aminotransferase Inhibitor OV329 And TSC/IS Expansions Ovid Therapeutics is upgraded from 'Hold' to 'Buy' as OV329 advances past safety hurdles at higher doses. The company's OV329 demonstrates best-in-class potential, with a superior safety and…
globenewswire.com Ovid Therapeutics to Participate in Upcoming Investor Conferences NEW YORK, June 04, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
globenewswire.com Ovid Therapeutics Appoints Leading Physician-Scientist and Biotech Innovator Anna Greka, M.D., Ph.D., to Board of Directors NEW YORK, June 03, 2026 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant…
globenewswire.com Ovid Therapeutics Reports Business Updates and First Quarter 2026 Financial Results Dosed first participant with OV4071, the first-ever oral potassium-chloride cotransporter 2 (KCC2) direct activator, in May 2026 in a Phase 1 study with healthy volunteers OV329 showed favorable…
proactiveinvestors.com AtaiBeckley wins OVID Health Silver Award for patient partnership in psychedelic trials AtaiBeckley Inc. (NASDAQ:ATAI, XETRA:9VC) said on Monday it had received the Silver Award in OVID Health's 2026 Patient Participant Index, recognizing its collaboration with the Psychedelic…
seekingalpha.com Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript Ovid Therapeutics Inc. (OVID) Discusses KCC2 Deep Dive and Pipeline Advances in CNS Disorders Transcript